Advent International to buy Suven Pharma for Rs 6,300 crore
Global private equity firm Advent International is expected to sign a binding agreement to buy the Hyderabad-based listed contract research and manufacturing services (CRAMS) company Suven Pharmaceuticals. As per the information from The Economic Times, Advent is using Cohance Lifesciences as the vehicle for the acquisition.
Advent's offer is being accepted by Suven's board in preference to a rival bid from Blackstone.
Also Read: Ciro Pharma To Set New Formulation Unit